Myasthenia Gravis Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

  • ID: 4542602
  • Report
  • 90 pages
  • Knowledge Sourcing Intelligence LLP
10 % OFF
until Jan 15th 2019
1 of 4

FEATURED COMPANIES

  • Akari Therapeutics
  • Argenx
  • Catalyst Pharmaceuticals
  • Curavac
  • Grifols Therapeutics LLC
  • Neurotune AG
  • MORE
Myasthenia Gravis Pipeline Analysis report covers 17 drugs currently in different phases of development. Myasthenia gravis (MG) is a neuromuscular disorder caused by impaired communication between nerves and muscles leading to the weakness and fatigue of the skeletal muscles. Symptoms of MG include slurred anf troubled speech, problems walking and lifting of objects, facial paralysis, difficulty in breathing, swallowing and chewing, extreme fatigue and double vision. It happens when normal communication between the nerve and muscle is interrupted at the neuromuscular junction-the place where nerve cells connect with the muscles they control.

The report provides Myasthenia Gravis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report are Akari Therapeutics, Bristol-Myers Squibb, Curavac, GT Biopharma, Inc. and Ra Pharmaceuticals among others.

Scope:
  • By Company
  • By Phase
  • By Molecule Type
  • By Region
  • By Route of Administration
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Akari Therapeutics
  • Argenx
  • Catalyst Pharmaceuticals
  • Curavac
  • Grifols Therapeutics LLC
  • Neurotune AG
  • MORE
1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region

2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology

3. Executive Summary

4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities

5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
  • Drug Name
  • Generic Name
  • Synonyms
  • Company
  • Collaborator
  • Route of administration
  • Target
  • Mechanism of Action
  • Technology
  • Molecule type
  • CAS Number
  • Weight
  • Chemical Formula
  • IUPAC name
  • ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region

6. Company profiling
6.1. Akari Therapeutics
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Alpha Cancer Technologies
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Apellis Pharmaceuticals, Inc.
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. Argenx
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. Bristol-Myers Squibb
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. Catalyst Pharmaceuticals
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. CSL Behring
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. Curavac
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. GlaxoSmithKline
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. Grifols Therapeutics LLC
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.11. GT Biopharma, Inc.
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.12. HanAll BioPharma Co., Ltd.
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.13. Neurotune AG
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT
6.14. Novartis
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.15. Pfizer
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.16. Ra Pharmaceuticals
6.16.1. Introduction
6.16.2. Financials
6.16.3. Products and Services
6.16.4. SWOT
6.17. Toleranzia AB
6.17.1. Introduction
6.17.2. Financials
6.17.3. Products and Services
6.17.4. SWOT
6.18. UCB Pharma
6.18.1. Introduction
6.18.2. Financials
6.18.3. Products and Services
6.18.4. SWOT
List of Tables
List of Figures
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Akari Therapeutics
  • Alpha Cancer Technologies
  • Apellis Pharmaceuticals, Inc.
  • Argenx
  • Bristol-Myers Squibb
  • Catalyst Pharmaceuticals
  • CSL Behring
  • Curavac
  • GlaxoSmithKline
  • Grifols Therapeutics LLC
  • GT Biopharma, Inc.
  • HanAll BioPharma Co., Ltd.
  • Neurotune AG
  • Novartis
  • Pfizer
  • Ra Pharmaceuticals
  • Toleranzia AB
  • UCB Pharma
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll